
The study aimed to evaluate the safety and effectiveness of the NO-independent sGC activator BI 685509 in patients with diabetic kidney disease and albuminuria. The Phase Ib trial included patients with type 1 or type 2 diabetes and varying degrees of kidney function. Patients were randomly assigned to receive BI 685509 or a placebo for 28 days. The results showed that BI 685509 was generally well tolerated, with some drug-related adverse events reported. The reduction in urinary albumin-to-creatinine ratio (UACR), a marker of albuminuria, was not statistically significant in the treatment groups compared to placebo. However, there were promising decreases in UACR in some patients, suggesting the need for further investigation.
Like
Save
Share